8-K: Grace Therapeutics Reports Q3 2026, GTx-104 FDA Date Set

Grace Therapeutics announced its third quarter 2026 financial results and provided a business update, highlighting the FDA's PDUFA target date for GTx-104.

Summary

• Reported a net loss of approximately $2.3 million, or $0.14 per share, for the three months ended December 31, 2025, a decrease from $4.2 million, or $0.36 per share, for the same period in 2024.
• The decrease in net loss was primarily due to a $1.7 million decrease in research and development expenses and a $1.1 million decrease in the change of fair value of derivative warrant liabilities.
• Research and development expenses for the quarter were $0.5 million, down from $2.2 million in the prior year, mainly due to the completion of the GTx-104 pivotal Phase 3 STRIVE-ON safety clinical trial.
• General and administrative expenses increased by $0.5 million to $2.0 million, primarily due to costs associated with GTx-104 pre-commercial planning.
• Cash and cash equivalents were $18.7 million as of December 31, 2025, a net decrease of $3.4 million compared to $22.1 million at March 31, 2025.
• The FDA established April 23, 2026, as the PDUFA target date for the review of the New Drug Application (NDA) for GTx-104 in the treatment of aneurysmal Subarachnoid Hemorrhage (aSAH).
• Data from the pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 was presented at the 2025 Society of Vascular and Interventional Neurology annual meeting.
• The STRIVE-ON trial met its primary endpoint, showing a 19% reduction in at least one incidence of clinically significant hypotension for GTx-104 patients (28%) compared to oral nimodipine (35%).
• GTx-104 patients also showed a 29% higher rate of favorable functional outcomes at 90 days and fewer intensive care unit (ICU) readmissions, ICU days, and ventilator days.
• The company secured approximately $4.0 million in additional funding in October 2025 through exercises of common warrants issued in September 2023.
• Development of GTx-102 and GTx-101 has been deprioritized in favor of focusing on GTx-104, with potential licensing or sale of these assets.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, driven by the significant progress of GTx-104 towards FDA approval, robust Phase 3 trial results, and a reduced net loss, despite a decrease in cash.

Positives

• Net loss significantly decreased to $2.3 million in Q3 2026 from $4.2 million in Q3 2025, indicating improved financial performance.
• FDA set a PDUFA target date of April 23, 2026, for GTx-104, signaling a clear regulatory pathway and potential near-term approval.
• The Phase 3 STRIVE-ON trial for GTx-104 met its primary endpoint, demonstrating a 19% reduction in clinically significant hypotension compared to oral nimodipine.
• GTx-104 showed superior clinical outcomes, with 29% more patients achieving favorable functional outcomes at 90 days and reduced healthcare resource utilization (ICU readmissions, ICU days, ventilator days).
• Successful warrant exercises generated $4.0 million in additional funding, strengthening the company's financial position.
• Management believes existing cash and cash equivalents of $18.7 million will be sufficient to sustain planned operations for at least 12 months.
• GTx-104, GTx-102, and GTx-101 have all been granted Orphan Drug Designation by the FDA, providing potential market exclusivity.

Negatives

• Cash and cash equivalents decreased by $3.4 million from March 31, 2025, to December 31, 2025.
• General and administrative expenses increased by $0.5 million, primarily due to pre-commercial planning costs for GTx-104.
• Eight deaths occurred in the GTx-104 arm of the STRIVE-ON trial compared to four in the oral nimodipine arm, although all deaths were attributed to the severity of the underlying disease and not the drug.
• Development of GTx-102 and GTx-101 has been deprioritized, indicating a narrower focus and potential divestment of these assets.

Risks

• The success and timing of regulatory submissions for the Phase 3 STRIVE-ON safety trial for GTx-104 are uncertain.
• Regulatory requirements or developments and the outcome of the NDA submission for GTx-104 could change or be unfavorable.
• Changes to regulatory pathways could impact the development and approval process.
• The company's ability to protect its intellectual property for its drug candidates is crucial for long-term value.
• Legislative, regulatory, political, and economic developments could adversely affect the company's operations and financial results.
• Actual results and the timing of events could differ materially from forward-looking statements due to various risks and uncertainties.

Future Outlook

Grace Therapeutics anticipates potential FDA approval for GTx-104 by the PDUFA target date of April 23, 2026, and is continuing pre-commercial planning, commercial team buildout, and product launch preparations. The company believes its current cash and cash equivalents will be sufficient to sustain planned operations through at least 12 months from the press release date. Management expects GTx-104 to play a very promising role in the treatment of aSAH patients and aims to maximize its long-term market value through its strong U.S. and international patent estate.

Management Comments

• "During our third quarter of fiscal 2026 we continued to execute on our clinical and corporate goals, led by our pre-commercial planning in anticipation of potential FDA approval of our New Drug Application (NDA) for GTx-104 for the treatment of aSAH."
• "Our NDA is supported by a robust data package, including positive results from our STRIVE-ON trial, which provided evidence of improved clinical outcomes in aSAH patients treated with GTx-104 as well as potential medical and pharmacoeconomic benefits of GTx-104 in the treatment of aSAH."
• "The standard of care for aSAH has not seen meaningful innovation in nearly 40 years, and we believe that if GTx-104 is approved, our STRIVE-ON trial results point to a very promising role for GTx-104 in the treatment of these patients."
• "We look forward to continuing to engage with the FDA during their review as they work toward the PDUFA target date of April 23, 2026."

Industry Context

StockSavvy.ai notes that the aSAH treatment landscape has seen little meaningful innovation in nearly 40 years, positioning GTx-104 as a potentially significant advancement if approved. The company's strategic focus on a rare disease with Orphan Drug Designation aligns with a common biopharma strategy to target high-unmet-need areas, which can offer market exclusivity and premium pricing. The deprioritization of other pipeline assets (GTx-101, GTx-102) indicates a strategic concentration of resources on the most promising near-term commercial asset, GTx-104, a typical approach for biopharma companies nearing commercialization.

Comparison to Industry Standards

• The 19% reduction in clinically significant hypotension for GTx-104 compared to oral nimodipine (28% vs 35%) in aSAH patients represents a meaningful improvement over the current standard of care, which has seen no significant innovation in nearly 40 years.
• The 29% increase in favorable functional outcomes at 90 days for GTx-104 patients suggests a superior clinical profile compared to existing treatments, which is a critical differentiator in the neurocritical care space.
• Reduced ICU readmissions, ICU days, and ventilator days for GTx-104 patients indicate potential pharmacoeconomic benefits, which are crucial for hospital adoption and payer reimbursement, aligning with trends in critical care where new therapies aim to reduce overall healthcare burden.
• The Orphan Drug Designation for GTx-104, GTx-102, and GTx-101 provides a competitive advantage with seven years of marketing exclusivity post-launch, a standard incentive for developing treatments for rare diseases, similar to other successful orphan drug developers.

Stakeholder Impact

• Shareholders: Potential for significant value appreciation upon GTx-104 approval and successful commercialization, supported by positive trial data and patent protection. Dilution from warrant exercises is a consideration.
• Patients (aSAH): Potential access to a novel, improved treatment option for a life-threatening condition with limited current innovation.
• Healthcare Professionals: New educational programs (CME) are being developed to address current challenges in treating aSAH patients, potentially leading to better patient management.
• Employees: Increased focus on GTx-104 may lead to growth in commercial and regulatory teams, while R&D personnel for deprioritized assets might face reassignments or impacts.

Next Steps

• Engage with the FDA during their review process for GTx-104 leading up to the PDUFA target date.
• Continue pre-commercial planning for GTx-104, including commercial team buildout.
• Prepare for product launch if GTx-104 receives FDA approval.
• Potentially license or sell deprioritized assets GTx-102 and GTx-101.

Key Dates

Recommendation

The setting of a PDUFA date for GTx-104, coupled with robust positive Phase 3 trial data demonstrating superior clinical and pharmacoeconomic outcomes over the current standard of care for a condition with significant unmet needs, represents a major de-risking event. The reduced net loss and sufficient cash runway further strengthen the investment case, indicating a clear path towards potential commercialization and significant value creation.

Keywords

Grace Therapeutics, GTx-104, aSAH, aneurysmal Subarachnoid Hemorrhage, nimodipine, FDA, PDUFA, STRIVE-ON, Phase 3 trial, biopharma, orphan drug, financial results, Q3 2026, cash runway, warrant exercise, drug development